Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have earned a consensus rating of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $25.20.

Several research firms have commented on EIKN. Weiss Ratings assumed coverage on Eikon Therapeutics in a research note on Monday, June 1st. They set a “sell (e-)” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Wedbush dropped their price target on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating for the company in a research report on Tuesday, May 12th. Finally, Wall Street Zen downgraded Eikon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, April 5th.

Eikon Therapeutics Trading Down 5.1%

Shares of NASDAQ EIKN opened at $9.01 on Thursday. The firm has a 50-day moving average of $10.19. Eikon Therapeutics has a 52-week low of $7.90 and a 52-week high of $17.40. The firm has a market capitalization of $487.79 million and a price-to-earnings ratio of -3.66.

Eikon Therapeutics (NASDAQ:EIKN) last released its quarterly earnings results on Monday, March 30th. The company reported ($26.23) earnings per share for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.